July 29, 2024

Meta-analysis finds Quality of Life improvements associated with ADHD medications

Quality of life (QoL) is defined as a person’s satisfaction with their life, measured across several dimensions including psychological, social, health, biological, and economic wellbeing. For adults, these are usually self-reported. In children and adolescents, they tend to be reported indirectly through parent- or caregiver questionnaires.  

Medications for ADHD include stimulants (methylphenidate and amphetamines) and non-stimulants (e.g., atomoxetine, clonidine, guanfacine, viloxazine). As QoL is related to ADHD symptoms’ severity, management of ADHD via medication could improve not only core symptoms but also QoL in people with ADHD.  

Noting the absence of meta-analytic evidence on the effects of ADHD medications on QoL, an international research team conducted a systematic review and meta-analysis of parallel or cross-over randomized clinical trials (RCTs) to estimate the effects of ADHD medication on QoL. They also performed secondary analyses to see if these effects differed in children and adolescents versus adults, as well as by class of medications, and if they were moderated by length of treatment.

Meta-analysis of four RCTs with a combined total of 950 participants with ADHD (45% adults) found a medium effect size improvement among those receiving amphetamines by comparison with those receiving placebo. There was no sign of publication bias, but there was wide variation (heterogeneity) in effect size estimated among the studies.  

Meta-analysis of four RCTs with a combined total of 1,094 participants with ADHD (57% adults) found a small-to-medium effect size improvement among those receiving methylphenidate by comparison with those receiving placebo. Again, there was no sign of publication bias, but wide variation in effect sizes among the studies.

The team could not explore whether length of treatment with the stimulants methylphenidate or amphetamines affected the results, or a subgroup analysis to test any differences in effects on QoL between children/adolescents and adults, since less than ten studies were included in each of the meta-analyses.

Finally, meta-analysis of eleven RCTs with a combined total of 3,344 participants with ADHD (63% adults) likewise found a small effect size improvement among those taking atomoxetine compared with those receiving placebo. Once again, there was no sign of publication bias, but wide variation in effect sizes among the studies.

With more than ten studies, the team was able to establish that for atomoxetine treatment, length of intervention – the studies ranged from 6 to 24 weeks – had no significant moderating effect. Similarly, they found no significant differences in effect on children and adolescents versus adults.  

A single RCT evaluating modafinil (a less addictive stimulant) treatment in adults found no improvements at any dose, whereas a single RCT testing non-stimulant guanfacine reported a medium effect size improvement in QoL.

The team concluded, “Overall, we found that methylphenidate, amphetamines, and atomoxetine were significantly more efficacious than placebo in improving QoL in people with ADHD. For atomoxetine, efficacy was significantly detected regardless of length of intervention or participant age ... our study demonstrated that, besides being efficacious in reducing ADHD symptomatology, stimulant and non-stimulant medications are effective in improving QoL in children, young people, and adults with ADHD, albeit with smaller effects compared those found for ADHD core symptoms severity. We found a medium effect for amphetamines and methylphenidate (both stimulant medications), and a small effect for atomoxetine (a non-stimulant).”

Alessio Bellato, Nadia J. Perrott, Lucia Marzulli, Valeria Parlatini, David Coghill, and Samuele Cortese, “Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life,” Journal of the American Academy of Child & Adolescent Psychiatry (2024), https://doi.org/10.1016/j.jaac.2024.05.023.

Related posts

No items found.

Meta-analysis: Cognitive Behavioral Therapy for Adult ADHD

A recent meta-analysis examined how well cognitive behavioral therapy (CBT) improves not just symptoms, but everyday functioning and quality of life in adults with ADHD. 

The Background:

ADHD in adults affects far more than attention or impulsivity. It often disrupts key areas of life: 

  • Education: Adults with ADHD tend to have lower GPAs, use fewer effective study strategies, achieve less academically, and are more likely to drop out.  
  • Work: They are more likely to experience job instability, including underperformance, unemployment, being fired, or frequent job changes.  
  • Social life: They often report smaller social networks, fewer close relationships, greater loneliness, and difficulty maintaining friendships or intimacy. Importantly, stronger social networks can help buffer (reduce) the impact of ADHD symptoms on daily life.  
  • Quality of life: Overall well-being is typically lower, affecting not only individuals but also their families and close relationships.

These broad impacts highlight a key issue: reducing symptoms does not automatically translate into better day-to-day functioning. 

CBT is a structured, skills-based therapy that helps people: 

  • Identify and challenge unhelpful thought patterns  
  • Reduce avoidance behaviors  
  • Build practical strategies for managing time, organization, and other executive functions (the mental skills used to plan, focus, and follow through)  

While both medication (especially stimulants) and CBT improve core ADHD symptoms, CBT is particularly aimed at improving real-world functioning. 

The Study:

The researchers analyzed studies involving adults diagnosed with ADHD (or showing clinically significant symptoms). They included: 

  • Randomized controlled trials (RCTs): studies comparing CBT to another treatment or to no treatment  
  • Within-subject studies: studies measuring change in the same individuals before and after CBT  

They focused specifically on outcomes beyond symptoms: 

  • Occupational functioning (work performance)  
  • Global functional impairment (overall daily functioning)  
  • Social relationships  
  • Academic functioning  
  • Quality of life  

The Results:

1.  Strongest Effects: Occupational functioning
CBT showed consistently strong improvements in work-related functioning compared to control groups, both immediately after treatment and at follow-up. This was the most robust finding across domains. 

2. Moderate Improvement: Global Functional Impairment
CBT led to moderate improvements in overall daily functioning, with some evidence that gains persist over time. In studies tracking individuals over time, improvements were even stronger at follow-up. 

3. Modest Gains: Social Relationships
CBT produced small to moderate improvements in social functioning. Benefits were present both after treatment and at follow-up, but were less pronounced than in work-related outcomes. 

4. Limited Effects: Academic Functioning
There were moderate short-term gains when CBT was compared to control groups, but these did not persist at follow-up. Within-subject studies showed only small improvements overall. 

5. Modest and Inconsistent Effects: Quality of Life
Improvements in quality of life were small when compared to control groups and often did not last. However, studies tracking individuals over time showed moderate improvements, suggesting some benefit that may not always show up clearly in between-group comparisons. 

Overall, the findings suggest: 

  • CBT does improve real-world functioning, not just symptoms  
  • The strongest and most consistent benefits are in occupational (work) functioning  
  • Gains in social life, academics, and overall quality of life are more modest and variable  
  • Improvements in functioning do not always track directly with symptom reduction  

One notable nuance: CBT did not always outperform other active treatments (like medication or other therapies). This suggests that while CBT is effective, its benefits may partly overlap with broader therapeutic or support effects rather than relying on a single, unique mechanism. 

The Take-Away: 

CBT is a valuable, evidence-based treatment for adults with ADHD, especially for improving work functioning and overall daily life management. However, its impact on relationships, academic outcomes, and quality of life is more limited and less consistent, pointing to the need for more targeted or combined approaches in those areas. 

 

June 9, 2026

When ADHD and Epilepsy Overlap, Cognitive Impacts Add Up

The Background:

ADHD and epilepsy are the two most common neurological disorders in children and adolescents. Additionally, they appear as co-diagnoses more often than chance would predict. Roughly a quarter of children with epilepsy also have ADHD, and children with ADHD face a 2.5-times greater risk of developing epilepsy than their peers. 

Clinicians have long suspected that carrying both diagnoses compounds cognitive difficulties, but no rigorous quantitative review has mapped out exactly how much, or in what ways. This new meta-analysis now fills that gap. 

The Study:

The team pooled data from peer-reviewed studies that included children and adolescents diagnosed with both conditions alongside at least one comparison group: children with neither condition, children with epilepsy alone, or children with ADHD alone. To capture the breadth of thinking skills, they constructed a general intelligence factor drawing on six cognitive domains: 

  • Crystallized intelligence — accumulated knowledge and its application 
  • Fluid reasoning — tackling novel problems through logical thinking 
  • Working memory — holding and mentally manipulating information in the short term 
  • Processing speed — executing simple or well-practiced mental tasks quickly 
  • Reaction time — responding rapidly to basic stimuli 
  • Long-term memory and fluency — efficiently storing and later retrieving new information 

The Results:

Across eleven studies (995 participants), children and adolescents with both conditions scored moderately lower on general intelligence than those with epilepsy alone. The same pattern held across all six cognitive domains. Seven studies (785 participants) comparing the dual-diagnosis group with those who had ADHD alone found an equally consistent moderate deficit, replicated in every domain. 

The clearest signal emerged when researchers compared children and adolescents carrying both diagnoses to typically-developing peers. Seven studies covering 427 individuals revealed a substantially larger gap in general intelligence, with the effects of the two conditions appearing to be roughly additive, meaning the combined burden was approximately equal to the sum of each condition's individual impact. This pattern held across five of the six domains. 

The Interpretation:

The results come with meaningful caveats. Variability across individual studies was moderate in the first two comparisons and high in the third, reflecting real differences in how studies were designed, which populations they sampled, and how they measured cognition. While there was no sign of publication bias in the first group, it was not assessed in two of the three analyses. 

The authors describe “a widespread profile of cognitive dysfunction” in children and adolescents with both epilepsy and ADHD, while underscoring that the substantial variability between studies warrants caution in drawing overly precise conclusions. The findings nonetheless carry practical weight: children managing both conditions may need more intensive cognitive screening and support than current clinical practice routinely provides. 

June 3, 2026

Exercise May Ease Social Difficulties in Young People with ADHD, New Meta-Analysis Suggests

The focus on children and adolescents with ADHD often revolves around behavioral issues and academic difficulties, but the social struggles are real. Around 60% of youth with ADHD experience meaningful difficulties in social skills, reading social cues, and forming reciprocal relationships with peers. Over time, these struggles can raise the risk of anxiety and depression. 

Medication remains the primary treatment for ADHD, with stimulants like methylphenidate (Ritalin) being the most commonly prescribed. While effective at reducing core symptoms such as inattention and impulsivity, medication has not been shown to improve social behavior or peer relationships.

The Background: 

Exercise has recently emerged as a promising adjunctive therapy. A newly published meta-analysis examined whether structured physical activity can specifically improve social functioning in young people with ADHD. It builds on a previous review from 2015, addressing gaps that earlier work left open: social outcomes were rarely treated as a primary focus, and no prior analysis had systematically compared exercise types or asked how much exercise is actually needed to see benefits. 

The Study: 

The analysis included 13 randomized controlled trials involving 703 participants aged 6 to 18, all clinically diagnosed with ADHD. Only exercise programs lasting at least four weeks were considered. Studies that combined exercise with other therapies, such as psychotherapy, were excluded to isolate exercise's specific effects. 

The researchers used a technique called network meta-analysis, which allows different interventions to be compared against one another even when they haven't been tested head-to-head, alongside dose-response modeling to identify how much exercise produces the greatest benefit. 

  • Closed-skill exercise: takes place in stable, predictable environments where movements can be planned in advance  (such as in gymnastics, track and field, or strength training). 
  • Open-skill exercise: unfolds in dynamic settings that demand constant adaptation  (team sports such as basketball or soccer, and those requiring specific hand-eye coordination such as table tennis). 
  • Multicomponent exercise blends both: a session might begin with a structured, self-directed drill (closed-skill) before transitioning into reactive, opponent-driven play (open-skill). 
  • Mind-body exercise integrates movement, mental focus, and controlled breathing (includes practices like yoga, tai chi, and qigong). 

Results: 

The most striking results came from closed-skill exercise: across four studies involving 92 participants, it was associated with a very large reduction in social dysfunction. Open-skill exercise, by contrast, showed no measurable improvement across four studies with 91 participants. Multicomponent exercise (the group combining elements of both open- and closed-skill) reported large gains in two smaller studies with 33 participants.  

Mind-body exercise showed a moderate benefit across three studies involving 44 participants. 

The dose-response analysis offered a practically useful finding: 30 to 60 minutes of moderate-intensity exercise per day appeared to produce the best outcomes, with a minimum of roughly 15 to 30 minutes daily needed to achieve any meaningful benefit. 

The Take-Away: 

The results are encouraging but should be interpreted carefully. The number of studies in each category was small (two to three studies each), and sample sizes were modest, meaning the findings may not hold up as more evidence accumulates. The absence of publication bias is reassuring, as is the use of rigorous methodology, but this remains an early-stage evidence base. Larger, well-designed trials are needed before firm clinical recommendations can be made. 

For now, the findings position structured physical activity  (particularly closed-skill and multicomponent exercise) as a plausible complement to existing ADHD treatment, specifically targeting the social difficulties that medication tends not to address. The practical dose guidance is a useful starting point: around half an hour of moderate daily exercise as a minimum, with an hour as the apparent sweet spot. As low-risk additions to a treatment plan go, that’s a relatively accessible bar for most families to consider alongside professional guidance. 

May 24, 2026